William Blair Expects Stronger Earnings for Twist Bioscience

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Research analysts at William Blair upped their Q3 2025 earnings estimates for Twist Bioscience in a report issued on Monday, May 5th. William Blair analyst M. Larew now expects that the company will post earnings of ($0.52) per share for the quarter, up from their previous forecast of ($0.55). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.12) per share. William Blair also issued estimates for Twist Bioscience's Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.14) EPS, Q1 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($1.34) EPS.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%.

A number of other research analysts have also recently commented on TWST. Robert W. Baird cut their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Guggenheim reaffirmed a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Barclays cut their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $50.40.

Twist Bioscience Trading Down 5.5 %

Twist Bioscience stock traded down $1.79 during mid-day trading on Thursday, hitting $30.82. The company's stock had a trading volume of 1,158,651 shares, compared to its average volume of 968,895. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The company has a 50 day moving average of $38.63 and a 200-day moving average of $43.69. Twist Bioscience has a one year low of $30.72 and a one year high of $60.90. The stock has a market cap of $1.85 billion, a PE ratio of -9.12 and a beta of 2.54.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 2,402 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the transaction, the chief executive officer now directly owns 662,692 shares of the company's stock, valued at approximately $27,110,729.72. This represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Paula Green sold 918 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the sale, the senior vice president now directly owns 130,912 shares of the company's stock, valued at $5,355,609.92. The trade was a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,991 shares of company stock valued at $742,654 in the last 90 days. Insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

Large investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its holdings in Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after buying an additional 580 shares during the period. GAMMA Investing LLC raised its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after purchasing an additional 303 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience during the 3rd quarter worth about $34,000. Finally, Banque Transatlantique SA purchased a new position in shares of Twist Bioscience during the 4th quarter valued at about $43,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.